MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

148.01
+5.03
+3.52%
After Hours: 148.01 0 0.00% 16:01 05/25 EDT
OPEN
144.20
PREV CLOSE
142.98
HIGH
149.49
LOW
143.25
VOLUME
738.48K
TURNOVER
0
52 WEEK HIGH
189.00
52 WEEK LOW
117.64
MARKET CAP
9.22B
P/E (TTM)
-19.6769
1D
5D
1M
3M
1Y
5Y
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks · 5d ago
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Jazz Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 78 to 81. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. Is Jazz Pharmaceuticals ...
Investor's Business Daily · 05/17 18:13
Jazz Pharmaceuticals's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between quarters.
Benzinga · 05/17 14:18
Jazz Pharma Highlights Will Present Data Showcasing Clinical Advancements Across Oncology Portfolio At American Society Of Clinical Oncology Jun. 3-7, Congress Of European Hematology Association Jun. 9-12
Key data includes ASCO oral presentation of data from the Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, May 12, 2022
Benzinga · 05/12 15:59
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present seven abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – June 7, 2022, and eight abstracts at the 27th Annual Con...
PR Newswire · 05/12 15:57
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218.
Benzinga · 05/11 19:57
Insider Sell: Jazz Pharmaceuticals
MT Newswires · 05/11 17:52
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S.
Benzinga · 05/09 11:43
More
No Data
Learn about the latest financial forecast of JAZZ. Analyze the recent business situations of Jazz Pharmaceuticals Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

27.78%Strong Buy
61.11%Buy
11.11%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average JAZZ stock price target is 202.00 with a high estimate of 240.00 and a low estimate of 174.00.
High240.00
Average202.00
Low174.00
Current 148.01
EPS
Actual
Estimate
1.052.113.164.22
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 666
Institutional Holdings: 64.32M
% Owned: 103.22%
Shares Outstanding: 62.32M
TypeInstitutionsShares
Increased
135
5.37M
New
71
1.57M
Decreased
163
5.69M
Sold Out
67
479.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.11%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Chief Executive Officer/Director
Bruce Cozadd
President
Daniel Swisher
Chief Financial Officer/Executive Vice President
Renee Gala
Chief Operating Officer/Executive Vice President/Managing Director
Christopher Tovey
Executive Vice President/General Manager
Kimberly Sablich
Executive Vice President
Robert Iannone
Senior Vice President
Finbar Larkin
Senior Vice President
Neena Patil
Senior Vice President
Samantha Pearce
Chief Accounting Officer/Vice President - Finance
Patricia Carr
Lead Director/Independent Director
Rick Winningham
Independent Director
Jennifer Cook
Independent Director
Patrick Enright
Independent Director
Peter Gray
Independent Director
Heather Mcsharry
Independent Director
Seamus Mulligan
Independent Director
Kenneth O'Keefe
Independent Director
Anne O'Riordan
Independent Director
Norbert Riedel
Independent Director
Mark Smith
Independent Director
Catherine Sohn
No Data
No Data
About JAZZ
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.